EUVIMEDEUVIMED entdecken
Open Access

Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis

Henning Clausen, Elin Friberg, Katarina Lannering, Aki Koivu, Mikko Sairanen, Mats Mellander, Petru Liuba

JAMA Network Open · 24.06.2024 · 7 (6) · e2418097

DOI: 10.1001/jamanetworkopen.2024.18097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 24.06.2024. Verfasst von Henning Clausen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Lund University, Sweden. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Neonatal Screening, Dried Blood Spot Testing, Biomarkers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Congenital heart disease (CHD) is the most common human organ malformation, affecting approximately 1 of 125 newborns globally.

Objectives

Assessing the performance of 2 diagnostic tests using minimal amounts of dried blood spots (DBS) to identify high-risk CHD compared with controls in a Swedish cohort of neonates. Design, Setting, and Participants This diagnostic study took place in Sweden between 2019 and 2023 and enrolled full-term babies born between 2005 and 2023. All cases were identified through centralized pediatric cardiothoracic surgical services in Lund and Gothenburg, Sweden. Controls were followed up for 1 year to ensure no late presentations of high-risk CHD occurred. Cases were verified through surgical records and echocardiography. Exposure High-risk CHD, defined as cases requiring cardiac surgical management during infancy due to evolving signs of heart failure or types in which the postnatal circulation depends on patency of the arterial duct. Using 3-μL DBS samples, automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1; formerly known as soluble ST2) were compared against established CHD screening methods. Main Outcomes and Measures Performance of DBS tests to detect high-risk CHD using receiver operating characteristic curves; Bland-Altman and Pearson correlation analyses to compare IL-1 RL1 DBS with plasma blood levels.

Results

A total of 313 newborns were included (mean [SD] gestational age, 39.4 [1.3] weeks; 181 [57.8%] male). Mean (SD) birthweight was 3495 (483) grams. Analyzed DBS samples included 217 CHD cases and 96 controls. Among the CHD cases, 188 participants (89.3%) were high-risk types, of which 73 (38.8%) were suspected prenatally. Of the 188 high-risk cases, 94 (50.0%) passed pulse oximetry screening and 36 (19.1%) were initially discharged after birth without diagnoses. Combining NT-proBNP and IL-1 RL1 tests performed well in comparison with existing screening methods and enabled additional identification of asymptomatic babies with receiver operating characteristic area under the curve 0.95 (95% CI, 0.93-0.98). Conclusions and relevance In this diagnostic study, NT-proBNP and IL-1 RL1 DBS assays identified high-risk CHD in a timely manner, including in asymptomatic newborns, and improved overall screening performance in this cohort from Sweden. Prospective evaluation of this novel approach is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Defects, CongenitalNeonatal ScreeningDried Blood Spot TestingBiomarkersNatriuretic Peptide, BrainHumansInfant, NewbornFemaleMaleSwedenPeptide FragmentsCase-Control StudiesInterleukin-1 Receptor-Like 1 Protein

Substanzen

Biomarkerspro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainPeptide FragmentsInterleukin-1 Receptor-Like 1 Protein

Autor:innen und Institutionen

  • Medical Faculty, Lund University, Sweden.
  • Children's Heart Centre, Skane's University Hospital, Lund, Sweden.
  • Medical Faculty, Gothenburg University, Gothenburg, Sweden.
  • Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Revvity, Diagnostics Research & Development, Turku, Finland.

Zitieren

APA

Clausen, H., Friberg, E., Lannering, K., Koivu, A., Sairanen, M., Mellander, M., & Liuba, P. (2024). Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis. JAMA Network Open, 7(6), e2418097. https://doi.org/10.1001/jamanetworkopen.2024.18097

Vancouver

Clausen H, Friberg E, Lannering K, Koivu A, Sairanen M, Mellander M, et al. Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis. JAMA Network Open. 2024;7(6):e2418097. doi:10.1001/jamanetworkopen.2024.18097

BibTeX
@article{Clausen2024,
  author = {Clausen, Henning and Friberg, Elin and Lannering, Katarina and Koivu, Aki and Sairanen, Mikko and Mellander, Mats and Liuba, Petru},
  title = {Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2418097},
  doi = {10.1001/jamanetworkopen.2024.18097}
}
Kostenlos starten →